Unveiling Pharmacogenomics Insights into Circular RNAs: Toward Precision Medicine in Cancer Therapy

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 535 - 535

Published: April 5, 2025

Pharmacogenomics is revolutionizing precision medicine by enabling tailored therapeutic strategies based on an individual genetic and molecular profile. Circular RNAs (circRNAs), a distinct subclass of endogenous non-coding RNAs, have recently emerged as key regulators drug resistance, tumor progression, responses. Their covalently closed circular structure provides exceptional stability resistance to exonuclease degradation, positioning them reliable biomarkers novel targets in cancer management. This review comprehensive analysis the interplay between circRNAs pharmacogenomics, focusing their role modulating metabolism, efficacy, toxicity profiles. We examine how circRNA-mediated regulatory networks influence chemotherapy alter targeted therapy responses, impact immunotherapy outcomes. Additionally, we discuss emerging experimental tools bioinformatics techniques for studying circRNAs, including multi-omics integration, machine learning-driven biomarker discovery, high-throughput sequencing technologies. Beyond diagnostic potential, are being actively explored agents delivery vehicles. Recent advancements circRNA-based vaccines, engineered CAR-T cells, synthetic circRNA therapeutics highlight transformative potential oncology. Furthermore, address challenges standardization, reproducibility, clinical translation, emphasizing need rigorous validation frameworks facilitate integration into practice. By incorporating profiling pharmacogenomic strategies, this underscores paradigm shift toward highly personalized therapies. hold immense overcome enhance treatment optimize patient outcomes, marking significant advancement

Language: Английский

Products of abortive transcription can prime synthesis of chimeric oligonucleotides

Mathematical Biology and Bioinformatics, Journal Year: 2024, Volume and Issue: 19(2), P. 453 - 471

Published: Dec. 8, 2024

The aim of the study was to search for signal RNAs potentially utilized by bacteria intercellular interactions. This not limited a certain category regulatory RNAs, which are contained in large numbers all domains life. performed using RNA-seq data obtained wild-type strain E. coli and its mutant derivative (Δdps) lacking gene encoding nucleoid protein Dps. can bind is found membrane structures, indicates possibility participation their secretion. Since spectra intracellular secreted differed, it assumed that somehow selected Therefore, RNA sets with Dps-dependent secretion, we searched reads non-template nucleotides at ends, point nucleotide substitutions, insertions deletions, as well regularly detected chimeras. One chimera 9-mer GCCAAGGCG 5'-end transcript from fimA-fimI intergenic region 3'-end chosen detailed study. It product abortive transcription antisense promoter inside ravA gene. efficiently forms chimeras many including 5'-ends fragments shortened this terminus. Analysis partners different revealed coding sites genome, feature ability form stable secondary structures therefore cause stops or pauses. discovery witnesses they formed result primed synthesis rather than random ligation. possible biological role products, whose has been established first time, discussed.

Language: Английский